Immunotherapy Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Immunotherapy Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Bioterrorism
Pharma firm to develop therapy for acute radiation syndrome
February 8th, 2006
Hollis-Eden Pharmaceuticals, Inc., (HEPH) has formally advised the U.S. Department of Health and Human Services (HHS) of its intent to respond by the February 8, 2006, deadline to a request for proposal (RFP) for medical countermeasures to mitigate or treat neutropenia alone or in combination with comorbidities associated with acute radiation syndrome (ARS). Hollis-Eden views this RFP as an important initial procurement step by HHS to begin preparing the U.S. country for a nuclear terrorist event on U.S. soil. In its response to the RFP the company will continue to point out the facts surrounding the realities of a mass casualty nuclear scenario that experts predict...
Source: Immunotherapy Weekly (2006-02-08)
|
